Oslo, Norway, November 26, 2009.

Both the European Patent Office and the Patent Office in Russia have
issued decisions to grant a patent on Photocure's patent application
"PDT Acne". The granted patents will provide protection for the use
of the 5-ALA-ester methyl aminolevulinate (MAL- the active ingredient
in VisonacTM) and other 5-ALA-esters in the treatment of acne until
November 2025.

"We are very pleased with these decisions giving a strong patent
protection on Photocure's lead dermatology product", says Kjetil
Hestdal, President and CEO of Photocure. "Patent protection of our
products is key to succeed in the market".

VisonacTM is a photodynamic therapy that combines the VisonacTM cream
with illumination by a red light source to treat acne. Visonac(TM)
cream contains MAL. The cream is applied to the acne area to be
treated and after a short incubation time, the skin is illuminated
with red light. The PDT procedure kills bacteria and appears to have
a beneficial effect on sebaceous glands and inflammatory cells.

About acne:
Acne is a common skin condition which affects up to 85% of
adolescents. Each year, US dermatologists register nearly 3 million
visits concerning acne. Of those who seek medical advice from a
dermatologist, about 50% have moderate and 20% have severe acne.

Current therapies for these patients include oral antibiotics and
isotretinoin, both products that may have significant adverse
effects. There is thus a clear medical need for a safe and
efficacious topical treatment for acne patients.

For further information, contact:

President and CEO Kjetil Hestdal
E-mail: kh@photocure.no
Mobile: +47 913 19 535
Office: +47 22 06 22 10

CFO Christian Fekete
E-mail: cf@photocure.no
Mobile: +47 916 42 938
Office: +47 22 06 22 10

About Photocure:
Photocure is a Norwegian pharmaceutical company listed on the Oslo
Stock Exchange (OSE: PHO). The company develops and sells
pharmaceuticals and medical devices for the photodynamic treatment
and diagnosis of cancer and selected dermatology indications.

Photocure's commercial activities includes own marketing and sales in
selected markets as well as out-licensing to leading pharmaceutical
companies on a regional or global basis prior to phase III.

Photocure has one proprietary pharmaceutical product on the market:
Hexvix®, for the diagnosis of bladder cancer. Hexvix is approved in
EU and under priority review by FDA in the US. In addition, the
company has developed a proprietary light source, which is used in
combination with the Visonac(TM) cream. Through worldwide studies,
Photocure is continuously testing its products for new indications,
and the aim is to develop a pipeline of follow-on products based on
the Photocure Technology(TM) platform.

Photocure® and Hexvix® are registered trademarks of Photocure ASA.

For more information about Photocure, visit our website at
www.photocure.com.


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.